Banking

Aurinia Pharmaceuticals Shows Rising Relative Strength

When looking for the best stocks to buy and watch, focus on those with rising relative price strength.

One stock that fits that bill is Aurinia Pharmaceuticals (AUPH), which had its Relative Strength (RS) Rating upgraded from 73 to 84 Friday.




X



When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary RS Rating measures technical performance by showing how a stock’s price movement over the last 52 weeks measures up against that of the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 as they begin their biggest runs.


See How IBD Helps You Make More Money In Stocks


Aurinia Pharmaceuticals has moved more than 5% past a 16.39 entry in a first-stage consolidation, meaning it’s now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.

While the company’s bottom line growth decreased in the company’s most recent performance report from 0% to -54%, the top line rose 21,967%, up from 2,933% in the previous report.

Aurinia Pharmaceuticals earns the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. Maravai Lifesciences (MRVI) and Biontech Se Ads (BNTX) are also among the group’s highest-rated stocks.

YOU MIGHT ALSO LIKE:

Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders

 

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button